FDA allows wider use of 2 hepatitis drugs from Schering

03/11/2009 | Forbes

Schering-Plough received FDA clearance to market its hepatitis C drugs Pegintron and Rebetol for patients with compensated liver disease who no longer respond to previous treatment. The drugs are approved as initial treatment in patients age 3 and older.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA
NTA Life
Addison, TX
Chief Information Officer
Meridian Health Plan
Detroit, MI
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA